Roche is pulling private gene-sequencing firm Kapa Biosystems under its wing for an undisclosed amount in a move to ramp up its offering in next-generation sequencing.

The companies, which already share a solid working history, said they have signed a deal that strengthens Roche’s foothold in the field and, for Kappa, expands the firm’s global reach and access to clinical expertise. 

Kapa’s protein engineering technology is highly customisable and allows for the generation and screening of large numbers of enzyme variants, Roche said, noting that it enables rapid selection of tailored enzymes with improved performance for specific applications, thus speeding up product development timelines.

The transaction remains subject to closing conditions, and financial details were kept under wraps.

Last week Roche announced plans to buy GeneWEAVE BioSciences for $425 million, securing access to the group’s Smarticles technology which is able to quickly identify multidrug-resistant organisms and assesses antibiotic susceptibility directly from clinical samples.